Type II diabetes is one of the most prevalent metabolic disorders both in low and high-income countries being managed by improving insulin secretion and controlling blood glucose levels by administering oral hypoglycemic drugs such as α-glucosidase inhibitors, sulfonylureas, and biguanides. Here, INS is linked to metabolic disease.